La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

NRx Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

NRx Pharmaceuticals' Il CEO è Steve Willard, nominato in Jul2022, e ha un mandato di 2.08 anni. la retribuzione annua totale è $ 500.00K, composta da 100% di stipendio e 0% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.97% delle azioni della società, per un valore di $ 181.65K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.1 anni e 2.1 anni.

Informazioni chiave

Steve Willard

Amministratore delegato

US$500.0k

Compenso totale

Percentuale dello stipendio del CEO	100.0%
Mandato del CEO	2.2yrs
Proprietà del CEO	1.0%
Durata media del management	2.2yrs
Durata media del Consiglio di amministrazione	1.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Steve Willard rispetto agli utili di NRx Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$26m
Dec 31 2023	US$500k	US$500k	-US$30m
Sep 30 2023	n/a	n/a	-US$36m
Jun 30 2023	n/a	n/a	-US$39m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$1m	US$234k	-US$40m

Compensazione vs Mercato: La retribuzione totale di Steve ($USD 500.00K ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: La retribuzione di Steve è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Steve Willard (63 yo)

2.2yrs

Mandato

US$500,000

Compensazione

Mr. Stephen H. Willard, also known as Steve, Esq. serves as Acting Corporate Secretary at NRx Pharmaceuticals, Inc. He serves as Chief Executive Officer and Director at NRx Pharmaceuticals, Inc. since July...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jonathan Javitt	Co-Founder	less than a year	US$630.20k	13.82% $ 2.5m
Stephen Willard	Acting Corporate Secretary	2.2yrs	US$500.00k	0.98% $ 178.5k
Richard Narido	CFO & Treasurer	less than a year	US$298.02k	0% $ 0
Riccardo Panicucci	Chief Manufacturing & Technology Officer	3.7yrs	US$240.00k	Nessun dato
Suzanne Messere	Investor Relations	no data	Nessun dato	Nessun dato
Philip Lavin	Chief Methodologist	no data	Nessun dato	Nessun dato
Matthew Duffy	Chief Business Officer	1.5yrs	Nessun dato	Nessun dato

2.2yrs

Durata media

63yo

Età media

Gestione esperta: Il team dirigenziale di NRXP è considerato esperto (durata media dell'incarico 2.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jonathan Javitt	Co-Founder	less than a year	US$630.20k	13.82% $ 2.5m
Stephen Willard	Acting Corporate Secretary	2.2yrs	US$500.00k	0.98% $ 178.5k
Chaim Hurvitz	Independent Director	3.3yrs	US$52.50k	2.07% $ 376.5k
Patrick Flynn	Independent Director	3.3yrs	US$67.50k	0.55% $ 100.4k
Janet Rehnquist	Independent Director	less than a year	Nessun dato	Nessun dato
Dennis McBride	Independent Director	less than a year	Nessun dato	Nessun dato

1.5yrs

Durata media

66.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di NRXP non è considerato esperto (durata media del mandato 2.1 anni), il che suggerisce un nuovo consiglio.

NRx Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

NRx Pharmaceuticals, Inc., Annual General Meeting, Oct 08, 2024

NRx Pharmaceuticals, Inc. Announces Resignation of Stephen Willard as Chief Executive Officer

NRx Pharmaceuticals, Inc. Appoints Dennis McBride to Its Board of Directors

Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors

NRx Pharmaceuticals, Inc., Annual General Meeting, Dec 19, 2023

NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer

Recent updates

NRx Pharmaceuticals, Inc., Annual General Meeting, Oct 08, 2024

NRx Pharmaceuticals, Inc. Announces Resignation of Stephen Willard as Chief Executive Officer

NRx Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 14, 2024

NRx Pharmaceuticals Receives Letter from the Listing Qualifications Staff of the Nasdaq Regarding Market Value of Listed Securities

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Alignment with FDA on Pediatric Study Plan for NRX-100 (ketamine)

NRx Pharmaceuticals, Inc. to Proceed with Two New Drug Applications in 2024

NRx Pharmaceuticals, Inc. Appoints Dennis McBride to Its Board of Directors

NRx Pharmaceuticals, Inc. Presents Landmark Trial of Nrx-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: Nrx-101 Is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression

NRx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results

NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression

NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.0031 million.

NRx Pharmaceuticals Demonstrates Compliance with the Nasdaq Bid Price Requirement in Listing Rule 5550(a)(2)

NRx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics

NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

NRx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 28, 2024

NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

New major risk - Share price stability

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

Panel Grants NRx Pharmaceuticals Request for an Exception to Nasdaq Listing Rules Until April 16, 2024, to Demonstrate Compliance with the Rule

NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

NRx Pharmaceuticals Demonstrates Compliance with Nasdaq MVLS Standard

Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors

Price target increased by 7.1% to US$3.75

NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

NRx Pharmaceuticals, Inc., Annual General Meeting, Dec 19, 2023

New major risk - Financial position

NRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain

NRx Pharmaceuticals Receives Formal Notice from the Listing Qualifications Staff of Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

NRx Pharmaceuticals Announces Strategic Acceleration of its Plans to Develop Commercial Form of NRX-100 (intravenous ketamine) to Treat Acute Depression and Suicidality

NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain

NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer

NRx Pharmaceuticals, Inc. Announces New Data That Demonstrates Potent in Vitro Activity of NRx-101

NRx Pharmaceuticals Announces Submission of an Investigational New Drug Application for NRX -101 in the Treatment of Chronic Pain

NRx Pharmaceuticals, Inc. announced that it expects to receive $1.2 million in funding

Co-Founder recently bought US$64k worth of stock

New major risk - Share price stability

NRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

NRx Pharmaceuticals Receives Written Notification from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(b)(2)(A) – Market Value of Listed Securities

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.285501 million.

Price target increased by 7.7% to US$3.50

NRx Pharmaceuticals, Inc. Reports Minutes of U.S. Food and Drug Administration Meeting on Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality

NRx Pharmaceuticals, Inc. Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101

NRx Pharmaceuticals, Inc. Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted

Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc.

CEO & Director recently bought US$59k worth of stock

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements

Independent Director recently bought US$515k worth of stock

High number of new and inexperienced directors

NRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

NRx Pharmaceuticals, Inc. Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process

NRx Pharmaceuticals, Inc. announced that it has received $10 million in funding

NRx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 15, 2022

NRx Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

NRx Pharmaceuticals, Inc. Announces the Appointment of Stephen Willard as its Chief Executive Officer

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media